Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02893423 · ClinicalTrials.gov registry record · NA
Ropivacaine Transversus Abdominis Plane Blocks for Cesarean Section Analgesia
A NA study, sponsored by Maimonides Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT02893423: Clinical Trial NA study, sponsored by Maimonides Medical Center.
NCT02893423 is a NA study that was terminated before completion, run by Maimonides Medical Center. The registered enrollment target is 51 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02893423, a NA study, was terminated before completion, sponsored by Maimonides Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
With this research the investigators hope to determine the lowest dose of ropivacaine used in transversus abdominis plane (TAP) blocks that can effectively treat pain in women after cesarean section (c-section).
Primary Outcome
Severity of postoperative pain will be assessed using(VAS) scale. Post-operative pain scale name: Visual Analog Scale (0-10) with 0 being no-pain and 10 being maximum pain.
Interventions
- DRUG Ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2013-01-01 |
| Est. Completion | 2016-09-30 |
| Phase | NA |
Why NCT02893423 stopped before completion
NCT02893423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Ropivacaine is the first listed.
NCT02893423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02893423 about?
NCT02893423 is a clinical study titled "Ropivacaine Transversus Abdominis Plane Blocks for Cesarean Section Analgesia". With this research the investigators hope to determine the lowest dose of ropivacaine used in transversus abdominis plane (TAP) blocks that can effectively treat pain in women after cesarean section (c-section).
What is the current status of trial NCT02893423?
This trial is currently terminated. It is a NA study. The enrollment target is 51 participants. The study started on 2013-01-01. Estimated completion is 2016-09-30.
What interventions are being tested in trial NCT02893423?
The interventions under investigation include: Ropivacaine (DRUG).
Who is sponsoring clinical trial NCT02893423?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02893423's enrollment target sits among peer trials
51 1279th of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI